ONCO Onconetix, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1782107 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-51.3%
TTM net income YoY76.9%
TTM EPS YoY216.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin80.4%
Operating margin-2,525.0%
Net margin-1,578.8%
FCF margin—
EBITDA margin-2,522.7%
Returns
ROE-105.2%
ROA-57.4%
ROIC (approx.)-195.9%
Asset turnover0.04x
Leverage & solvency
Liabilities / assets18.0%
Debt / equity0.00x
Current ratio2.21x
Interest coverage-52.44x
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $815,371 | $2.52M | $58,465 | — | — |
| Cost of revenue | $182,458 | $1.47M | $1.19M | — | — |
| Gross profit | $632,913 | $1.06M | -$1.13M | — | — |
| R&D expense | — | $154,359 | $1.95M | $4.13M | $1.33M |
| SG&A expense | $7.04M | $11.23M | $14.77M | $9.35M | $2.09M |
| Operating income | -$17.86M | -$56.49M | -$36.03M | -$13.48M | -$3.42M |
| Interest expense | $751,005 | $873,433 | $671,625 | — | — |
| Pretax income | -$14.03M | -$59.74M | -$37.42M | -$13.42M | — |
| Income tax | $525 | -$1.05M | -$12,593 | $3.16T | $675.73B |
| Net income | -$14.03M | -$58.69M | -$37.41M | -$13.42M | -$3.42M |
| EBITDA | -$17.84M | -$55.76M | -$35.99M | -$13.47M | -$3.41M |
| EPS (basic) | -16.56 | -1,823.39 | -87.45 | -1.10 | -1.26 |
| EPS (diluted) | -16.56 | -1,823.39 | -87.45 | -1.10 | -1.26 |
| Dividends declared per share | — | — | — | 1.23 | — |
| Weighted avg. shares (diluted) | 937,690 | 32,301 | 427,784 | 12.27M | 3.20M |
| Banking | |||||
| Deposits | — | $3.50M | $3.50M | — | — |
| Balance sheet | |||||
| Cash & equivalents | $5.22M | $646,500 | $4.55M | $25.75M | $1.93M |
| Receivables | $296,866 | $25,717 | $149,731 | — | — |
| Inventory | $149,961 | $64,079 | $364,052 | — | — |
| Current assets | $6.07M | $950,267 | $5.84M | $26.26M | $3.07M |
| PP&E, net | $37,085 | $62,896 | $60,654 | $14,089 | $11,502 |
| Goodwill | $18.55M | $18.55M | $55.68M | — | — |
| Intangibles | — | — | $25.41M | — | — |
| Total assets | $24.93M | $28.18M | $87.52M | $26.31M | $3.08M |
| Current liabilities | $9.14M | $18.29M | $17.19M | $3.92M | $1.64M |
| Total liabilities | $9.16M | $18.57M | $21.88M | $3.92M | $1.64M |
| Shareholders' equity | $15.76M | $8.54M | -$5.60M | $22.39M | $1.45M |
| Shares outstanding | 31,198 | 138,270 | 558,099 | 15.27M | 3.20M |
| Cash flow statement | |||||
| Operating cash flow | -$9.68M | -$10.50M | -$13.58M | -$8.68M | -$2.04M |
| Capital expenditure | — | $28,471 | $3,300 | $9,339 | $1,924 |
| Free cash flow | — | -$10.52M | -$13.58M | -$8.68M | -$2.05M |
| Investing cash flow | — | -$28,471 | -$8.65M | -$32,665 | -$1,924 |
| Financing cash flow | $14.45M | $6.74M | $1.04M | $32.53M | -$334,188 |
| Depreciation & amortization | $15,170 | $731,345 | $43,937 | $6,752 | $4,890 |
| Stock-based compensation | $74,267 | $438,653 | $329,760 | $1.97M | $130,141 |
| Share buybacks | — | — | — | $566,810 | — |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.